Which Arm Gets Vaccinated Could Play a Role in Your Immune Response
The arm you offer up for vaccination could impact your immediate immune response. But here's the catch: scientists still aren't sure if it's better to give a secondary booster shot to the same arm or a different one.
Currently, only a handful of studies have explored whether you should switch sides between a first and second jab, and the ones on COVID vaccines have produced mixed results.
Following the 2020 outbreak of COVID-19, for instance, researchers in Germany found that giving multiple jabs to the same arm produced better immune responses two weeks later.
Then, a follow-up study from researchers in the US found the exact opposite. According to that randomized trial, switching arms between shots resulted in a four-fold increase in COVID-specific antibodies four weeks after the second jab.
Get ready for yet another contradictory finding. Researchers in Australia are weighing in on the debate, and their experiments on mice and humans agree with the same-arm study.
The trial, led by Rama Dhenni from the Garvan Institute of Medical Research and Alexandra Carey Hoppé from the University of New South Wales (UNSW), involved 30 healthy participants who had not yet had COVID-19.
All participants received two shots of the Pfizer vaccine, three weeks apart – 20 had both shots in the same arm, while 10 got the booster in the opposite arm to the first jab.
Those in the same-arm group showed a boosted immune response in the week after their second shot, according to blood and lymph node analysis.
"Those who received both doses in the same arm produced neutralizing antibodies against SARS-CoV-2 significantly faster – within the first week after the second dose," explains Carey-Hoppé.
"These antibodies from the same arm group were also more effective against variants like Delta and Omicron," adds immunologist Mee Ling Munier from UNSW.
Still, the apparent immune boost from a same-arm vaccination was ultimately short-lived. Four weeks after the booster, those who received a jab in the same arm showed similar antibody levels to those who received a jab in the opposite arm.
This suggests that the strengthened immune response from same-arm vaccinations does not last longer than a month.
"If you've had your COVID jabs in different arms, don't worry – our research shows that over time the difference in protection diminishes," says Munier. "But during a pandemic, those first weeks of protection could make an enormous difference at a population level."
Further research is needed, but Munier suspects that this same-arm vaccine strategy could help achieve herd immunity faster.
To explore why that might be, Munier and colleagues used mouse models. When mice were given a second vaccine to the same side of the body, it increased their immune response in that side's lymph nodes.
Lymph nodes drain fluid from their respective sides of the body. When a vaccine is administered to one arm, it introduces the corresponding lymph node to a weakened pathogen (or its components).
Immune cells called macrophages, which guard the entry point to the lymph nodes, handcuff these invaders and take them to unique players called memory B cells (Bmems).
These long-lived cells memorize what the danger looks like for future reference, and they also enter a specialized factory within the lymph node to trigger the production of antibodies tailored to that specific invader.
In mouse models, when a second vaccine was given to the same side of the body, the draining lymph node's sentinel macrophages were already primed to respond to that threat.
This means they jumped to action faster, communicating with "large clusters of reactivated Bmems" to send 10 times as many Bmems into the antibody factory as the non-draining lymph node.
Similar to the mouse data, when 18 of the human participants had their lymph nodes biopsied with a fine needle, the researchers found those who received a same-arm jab had increased percentages of Bmems in these antibody factories.
While these results are intriguing and shed some much-needed light on how vaccines work to boost our immune systems, Dhenni and colleagues argue further research is needed to make any practical recommendations.
The new findings may be more relevant to initial boosters given in quick succession, for instance, not necessarily seasonal vaccines that can be given months, if not years, apart, when immune responses on both sides of the body have time to balance out.
"This is a fundamental discovery in how the immune system organizes itself to respond better to external threats – nature has come up with this brilliant system and we're just now beginning to understand it," says immunologist Tri Phan.
The study was published in Cell.
Brisk Walking Could Lower Your Risk of Heart Rhythm Abnormalities
A Small Drop in Vaccinations Could Spread Measles to Millions, Study Warns
This Severe Brain Disorder Is Common But Often Goes Undiagnosed
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why has there been a global surge of new Covid variant NB.1.8.1?
India is the latest country to report a surge in new Covid cases, as the latest variant NB.1.8.1 spreads across the globe. Cases have now been reported in Asian countries such as Thailand, Indonesia and China, while the UKHSA recorded the first 13 cases in England last week. However, the true numbers are unlikely to be known, given the significant decrease in the number of people testing compared to the figures seen during the global pandemic five years ago. NB.1.8.1 stemmed from the Omicron variant and was first detected in January this year. It has quickly spread across China and Hong Kong, and has now been recorded in several states across the United States and Australia. By late April, NB.1.8.1 comprised about 10.7 per cent of submitted sequences globally, according to the World Health Organization (WHO). This rose from just 2.5 per cent one month before. The WHO declared the NB.1.8.1 strain a 'variant under monitoring' on 23 May, which means scientists believe it could potentially affect the behaviour of the virus. Lara Herrero, a virologist from Griffith University in Australia, suspects that NB.1.8.1 spreads more easily than other variants. 'Using lab-based models, researchers found NB.1.8.1 had the strongest binding affinity to the human ACE2 receptor of several variants tested, suggesting it may infect cells more efficiently than earlier strains,' Dr Herrero wrote last month in The Conversation. Dr Chun Tang, GP at Pall Mall Medical, added: 'NB.1.8.1 isn't too different from the Omicron variant, but it does have some tweaks to its spike protein, which might make it spread a bit more easily or slip past some of our existing immunity. 'That said, early signs suggest it doesn't seem to cause more serious illness, but of course, we're still learning more about it.' 'Its spread has been identified in around 22 countries,' said Dr Naveed Asif, GP at The London General Practice. 'The WHO assesses the additional risk to the global public as currently low, and existing Covid-19 vaccines are considered effective in preventing severe disease.' However, Nimbus does appear to be more transmissible than previous variants, with notable increases reported in India, Hong Kong, Singapore, and Thailand, notes Dr Asif. Common symptoms of the NB.1.8.1 variant include a severe sore throat. fatigue, mild cough, fever, muscle aches and congestion. It has also been reported that some patients have experienced gastrointestinal symptoms such as nausea and diarrhoea. Healthcare experts have stressed, however, that there is no evidence that the new strain is more deadly or serious than previous variants, and that current Covid vaccines are expected to remain effective and protect anyone infected from severe illness.


Newsweek
2 hours ago
- Newsweek
Nurses Were Covid Heroes. Now They're Being Squeezed by Medicaid Cuts
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. New York City nurses are calling for reforms as an industry plagued by a "broken" health care system threatens their livelihoods and the future of their profession. Why It Matters Nurses were considered vital and lauded as heroes during the COVID-19 pandemic, when at the outset the National Institutes of Health highlighting their "critical roles and responsibilities" that included front-line patient care in hospitals; ensuring personalized, high-quality services irrespective of infectious conditions; and engaging in planning for outbreaks stemming from coronavirus-related outbreaks that could overwhelm health systems. "These are issues that have preceded the pandemic and will continue until hospitals make serious efforts to recruit and retain nurses and invest in safe patient care," Nancy Hagans, president of the New York State Nurses Association (NYSNA), told Newsweek. "We're also witnessing the effects of a broken healthcare system," she said. "Patients can't afford care, so they put it off, and they come into hospitals much sicker than they ever were. The looming Medicaid cuts will only make this worse. NYSNA nurses are trying to hold hospitals accountable and also do as much as possible on the policy front to expand access to care." What To Know Hagans said that she and other nurses have complained about a nursing shortage for years. "NYSNA nurses have always maintained that there are more than enough nurses, but hospitals refuse to make real efforts to recruit and retain nurses," Hagans said. "We are seeing many more grads entering the profession than nurses leaving. Through better working conditions, safe staffing, and pay and benefits that respect nurses, hospitals could address whatever staffing issues they create." However, NYSNA, New York's largest union and professional association for registered nurses, which represents over 42,000 nurses and health care professionals, has been vocal about recent actions by some hospital systems that are cutting costs as well as jobs. New York City nurses and organizations have warned for years that staffing reductions and dwindling budgets are negatively impacting the profession long-term. New York City nurses and organizations have warned for years that staffing reductions and dwindling budgets are negatively impacting the profession long-term. Photo-illustration by Newsweek/Getty/Canva Montefiore Moses and Weiler In February, dozens of Bronx nurses at Montefiore Moses and Weiler spoke out about purported overcrowding and minimized services in emergency departments and hospital floors, as well as some surgical and palliative care services. Montefiore recorded a 0.2 percent operating loss in the first quarter of 2025. The statement, provided to Newsweek, says that while finances remained consistent year over year, "the proposed changes to reimbursements for Medicare and Medicaid are drawing the attention of healthcare providers across the country." "As one of the largest employers and providers of healthcare in the Bronx and Westchester, we are navigating a challenging and uncertain healthcare environment," Montefiore officials said. "Yet, we remain committed to providing the highest quality care to our communities, and to evaluating opportunities to reduce expenses and diversify our payer mix. "We implore elected officials to continue partnering with institutions like ours, serving a patient population that is 85 percent covered by government payor, to ensure sustainable funding." NewYork-Presbyterian Hospital In May, the NYSNA criticized NewYork-Presbyterian Hospital, a nonprofit academic medical center in New York City, following the announcement of a 2 percent staffing cut across their system—calling it "outrageous and deeply offensive" due to NYP being the city's wealthiest hospital system and one of the country's most financially stable. "Given current macroeconomic realities and anticipated challenges ahead, we have made the difficult decision to reduce our workforce by approximately 2 percent," an NYP spokesperson told Newsweek. "Where possible, we are working diligently to identify new and similar roles for impacted team members. "To elaborate, the healthcare environment continues to evolve, including changes to Medicaid and cuts to research grants to our medical school partners. In addition to these external factors, we are seeing fewer inpatients than expected and incurring higher expenses than projected. Focusing on improving efficiencies and managing expenses is a prudent action that will enable us to continue our mission of providing excellent care for our patients and communities." Hagans said that hospitals like Presbyterian, "with hefty amounts of cash on hand and historic executive pay," should be doing all they can to maintain and expand care rather than cut it. Albany Medical Center On June 5, nurses at Albany Medical Center called out the hospital for its ongoing refusal to address the staffing crisis and protect patient care. The criticism was in response to the nurses providing an update on the hospital's responses to a State Department of Health (DOH) report that found more than 500 violations, including 480 relating to safe staffing standards and 24 procedural violations. The violations were found across 26 different units, including 32 specifically within the neonatal intensive care unit, according to NYSNA. Almost a year after its initial investigation, and following several rejected correction plans, the DOH has yet to issue fines or prompt substantive change from the hospital, according to NYSNA. They called on the Albany Med Board of Directors to hold the hospital accountable. Nearly a year after its first investigation and several rejected correction plans, the DOH has yet to issue fines or spur substantive change from the hospital. Roughly 1,000 nurses signed a petition calling on Albany Med to negotiate a fair contract that will help address the staffing crisis. "There have been no nursing cuts at Albany Medical Center," Sue Rajchel, spokesperson for Albany Med, told Newsweek. "That is why we welcomed 300 new nurses in 2024 and are committed to hiring 400 nurses in 2025. "Our workforce is our greatest asset. We are continuing to negotiate with the union in good faith. We remain confident that our most recent contract proposal, which includes robust wage increases and enhanced benefits, is strong and fair. We will continue to listen to our nurses and advocate for them as we always have." What People Are Saying Nancy Hagans, president of the New York State Nurses Association, told Newsweek: "Less nurses compromises care. Period. The recent layoffs at Presbyterian will affect children and vulnerable patients most dramatically. Presbyterian has said that the impacted services will continue at other campuses, but for many, traveling long distances for care puts that care out of reach." What Happens Next "For nurses who know these cuts will negatively impact their communities, it's extremely demoralizing. But NYSNA nurses will keep fighting," Hagans said.
Yahoo
4 hours ago
- Yahoo
BIOSeedin Innovation Partnering Conference 2025: Spotlight on China's Biopharma Trailblazers and Global Collaboration
China's influential innovative drug asset cooperation platform NEWARK, Del., June 9, 2025 /PRNewswire/ -- BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSeedin, BIOS has attracted cutting-edge biotech startups and top investment firms globally. It serves as a crucial platform for fostering collaboration between China's biopharma sector and global markets, facilitating partnerships, therapeutic asset licensing, and investment networking. The 5th annual BIOSeedin Innovation Partnering Conference solidified its role as a nexus for global biopharma innovation, attracting more than 2,000 registrants from 10 countries. Senior executives and investors dominated the audience, with 61.66% holding C-suite, BD, or investment roles. The event facilitated 7,275 meeting requests. Confirmed deals across oncology, rare diseases, and next-gen modalities. MNCs including Merck & Co., Pfizer and Bayer emerged as top targets, with key accounts receiving over 50 meeting requests each. Key Insights from BIOS Discussions Dr. Yi Zhu, Founder and CSO of Biokin Pharma, framed China as a "translational research powerhouse", uniquely positioned to de-risk high-impact modalities. "Our cost-efficient clinical execution enables rapid validation of novel ADCs and gene-editing platforms," he noted, citing Biokin's Phase II PD-1xLAG-3 bispecific antibody as evidence of China's ability to advance complex biologics. His call for investors to prioritize high-risk, high-reward assets resonated across sessions, particularly as Chinese startups now contribute 38% of global ADC patents. John Zhu, CEO of DualityBio, challenged conventional innovation metrics during a standing-room-only session. "True differentiation isn't about target novelty but biomarker-driven clinical value," he asserted, showcasing DualityBio's tumor-activated ADC linker technology. His critique of "therapeutic crowding" aligned with investor interest in China's precision medicine pipelines, particularly in NSCLC and triple-negative breast cancer. Dr. Zhang Lianshan, EVP of Hengrui Pharma, grounded discussions in localization imperatives. "Globalization starts with domestic validation," he emphasized, detailing Hengrui's strategy to leverage China's 140 million cancer patient registry for accelerated oncology trials. His case study on a Claudin 18.2-targeted therapy — now in global Phase III — highlighted China's evolving role from fast follower to protocol co-designer. Jacky Jiang, BD Head at CSPC Pharma, outlined a pragmatic blueprint for strategic asset curation. "Align R&D with unmet needs, technical strengths, and M&A agility," he advised, referencing CSPC's recent acquisition of a CRISPR-Cas12Max delivery platform. His prediction that non-viral gene therapies will dominate rare disease investments by 2026 drew vigorous investor follow-ups. 40 companies gave roadshows and brought abundant assets The BIOSeedin 2025 roadshow spotlighted China's accelerating leadership in next-generation therapies, with 40% of showcased assets featuring breakthrough modalities like Phase II PD-1xLAG-3 bispecifics for NSCLC, preclinical Claudin 18.2xCD3 T-cell engagers, and tumor microenvironment-activated ADC linkers — technologies where Chinese firms now hold 32% of global patents. Rare disease innovations included non-viral CRISPR-Cas12Max therapies for retinal disorders (90% primate model efficacy) and Duchenne MD gene therapies, while metabolic/CNS advances featured dual GLP-1/GIP agonists outperforming competitors in weight loss trials and tau-targeting Alzheimer's mAbs. With 50% of programs in Phase I/II (including 10 breakthrough-designated assets) and two Phase III candidates nearing 2026 NDAs — a bispecific NSCLC antibody leveraging China's genomic databases and a non-opioid TRPV1-ATP analgesic — the portfolio underscores China's evolution from fast follower to global innovator, combining cost-efficient development with patient-centric therapeutic engineering. Building on this year's success, BIOSeedin 2026 will expand its global footprint with dedicated tracks for European and North American attendees. As Dr. Zhu Yi concluded, "China's biotech sector is not just catching up — it's redefining innovation. We invite global partners to join this journey, where collaboration transcends borders and accelerates patient-centric breakthroughs." Join us next year to explore investment opportunities, forge transformative partnerships, and shape the future of biopharma innovation. View original content: SOURCE bioSeedin Sign in to access your portfolio